Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Gastroenterology, Kurashiki Central Hospital, Kurashiki, Japan.
J Gastroenterol Hepatol. 2020 Jan;35(1):37-42. doi: 10.1111/jgh.14764. Epub 2019 Jul 28.
Bleeding is an inevitable and often severe complication after endoscopic sphincterotomy (EST). We aimed to investigate the factors associated with post-EST bleeding in patients treated with anticoagulants.
The data of patients who underwent EST at 15 hospitals between July 2015 and June 2017 were extracted. We investigated the incidence of post-EST bleeding and risk factors for bleeding in patients treated with anticoagulants.
One hundred forty-nine patients undergoing EST who met the inclusion criteria were included in this study. The total-EST bleeding (bleeding occurring during or after EST) rate did not differ between the heparin replacement (8.0%, 6/75) and continuation (16.6%, 2/12; P = 0.37) groups of warfarin users. The total-EST-bleeding rate in the heparin replacement group (12.9%, 4/31) was significantly higher than that in the continuation group (0%, 0/31; P = 0.016) in direct oral anticoagulant (DOAC) users. The rate of total-EST bleeding with continuation of DOAC (0%, 0/31) was significantly lower with continuation of warfarin (16.6%, 2/12; P = 0.021). During-EST bleeding (bleeding occurring during EST) (P = 0.0083) and precut (P = 0.033) were significant risk factors for post-EST bleeding in all 149 patients. Heparin replacement was only a significant risk factor for total-EST bleeding (P = 0.033) in DOAC users.
Heparin replacement was a significant risk factor for post-EST bleeding in DOAC users; however, there was no significant difference between the bleeding rate of heparin replacement and that of continuation groups in patients taking warfarin. During EST and precut were significant risk factors for post-EST bleeding in all patients treated with anticoagulants.
内镜下括约肌切开术(EST)后出血是一种不可避免且常很严重的并发症。我们旨在研究接受抗凝治疗的患者中与 EST 后出血相关的因素。
提取 2015 年 7 月至 2017 年 6 月期间在 15 家医院接受 EST 的患者的数据。我们调查了接受抗凝治疗的患者中 EST 后出血的发生率和出血的危险因素。
符合纳入标准的 149 例接受 EST 的患者被纳入本研究。华法林使用者中肝素替代(8.0%,6/75)和继续治疗(16.6%,2/12;P=0.37)两组的总 EST 出血(EST 期间或之后发生的出血)率无差异。肝素替代组(12.9%,4/31)的总 EST 出血率明显高于继续治疗组(0%,0/31;P=0.016)。继续使用华法林的总 EST 出血率(16.6%,2/12)明显高于继续使用达比加群(0%,0/31;P=0.021)。所有 149 例接受抗凝治疗的患者中,EST 期间出血(P=0.0083)和预切开(P=0.033)是 EST 后出血的显著危险因素。肝素替代仅在达比加群使用者中是 EST 后出血的显著危险因素(P=0.033)。
肝素替代是达比加群使用者 EST 后出血的显著危险因素;然而,在接受华法林治疗的患者中,肝素替代组和继续治疗组的出血率无显著差异。在所有接受抗凝治疗的患者中,EST 期间和预切开是 EST 后出血的显著危险因素。